Evidence map›Paper›PMID 37425702›Full record

ArticlebioRxiv : the preprint server for biology2023

Two Classes of DNA Gyrase Inhibitors Elicit Distinct Evolutionary Trajectories Toward Resistance in Gram-Negative Pathogens.

Semen A Leyn, James E Kent, Jaime E Zlamal, Marinela L Elane, Maarten Vercruysse, Andrei L Osterman

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Semen A LeynSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
James E KentSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Jaime E ZlamalSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Marinela L ElaneSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Maarten VercruysseRoche Pharma Research and Early Development, Immunology, Inflammation, and Infectious Diseases, Basel, Switzerland.
Andrei L OstermanSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
Sanford Burnham Prebys Medical Discovery Institute · USRoche (Switzerland) · CH

Funding

Comparative resistomics of Gram-negative bacterial pathogensR01AI167977 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ANDREI L OSTERMAN · 2022 to 2026
$3.7M
NIAID NIH HHS R01 AI167977
6 · The paper itself

Abstract

Comprehensive knowledge of mechanisms driving the acquisition of antimicrobial resistance is essential for the development of new drugs with minimized resistibility. To gain this knowledge, we combine experimental evolution in a continuous culturing device, the morbidostat, with whole genome sequencing of evolving cultures followed by characterization of drug-resistant isolates. Here, this approach was used to assess evolutionary dynamics of resistance acquisition against DNA gyrase/topoisomerase TriBE inhibitor GP6 in

Identifiers

PMID37425702
PMCPMC10327078
OpenAlexW4382644605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.